Latest Insider Transactions at Skye Bioscience, Inc. (SKYE)
This section provides a real-time view of insider transactions for Skye Bioscience, Inc. (SKYE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Skye Bioscience, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Skye Bioscience, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
Tuan Tu Diep Chief Development Officer |
SELL
Open market or private sale
|
Direct |
19,489
-19.15%
|
$77,956
$4.99 P/Share
|
|
Nov 18
2024
|
Kaitlyn Melanie Arsenault Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
43,206
-20.62%
|
$172,824
$4.99 P/Share
|
|
Nov 18
2024
|
Punit Dhillon Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
82,546
-20.02%
|
$330,184
$4.99 P/Share
|
|
Nov 18
2024
|
Paul A. Grayson Director |
SELL
Open market or private sale
|
Direct |
86,244
-24.93%
|
$344,976
$4.99 P/Share
|
|
Nov 15
2024
|
Tuan Tu Diep Chief Development Officer |
SELL
Open market or private sale
|
Direct |
85
-0.08%
|
$425
$5.55 P/Share
|
|
Nov 15
2024
|
Kaitlyn Melanie Arsenault Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
190
-0.09%
|
$950
$5.55 P/Share
|
|
Nov 15
2024
|
Punit Dhillon Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
364
-0.09%
|
$1,820
$5.55 P/Share
|
|
Nov 15
2024
|
Paul A. Grayson Director |
SELL
Open market or private sale
|
Direct |
307
-0.09%
|
$1,535
$5.55 P/Share
|
|
Sep 13
2024
|
Andrew J. Schwab Director |
SELL
Open market or private sale
|
Indirect |
13,837
-0.13%
|
$83,022
$6.06 P/Share
|
|
Sep 13
2024
|
5 Am Partners Vii, LLC |
SELL
Open market or private sale
|
Indirect |
13,837
-0.13%
|
$83,022
$6.06 P/Share
|
|
Sep 11
2024
|
Andrew J. Schwab Director |
SELL
Open market or private sale
|
Indirect |
252,500
-2.27%
|
$1,515,000
$6.6 P/Share
|
|
Sep 11
2024
|
5 Am Partners Vii, LLC |
SELL
Open market or private sale
|
Indirect |
252,500
-2.27%
|
$1,515,000
$6.6 P/Share
|
|
Aug 26
2024
|
Punit Dhillon Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
15,727
+3.67%
|
-
|
|
Mar 13
2024
|
Andrew J. Schwab Director |
BUY
Grant, award, or other acquisition
|
Indirect |
450,000
+5.09%
|
$4,500,000
$10.0 P/Share
|
|
Mar 13
2024
|
5 Am Partners Vii, LLC |
BUY
Open market or private purchase
|
Indirect |
450,000
+5.09%
|
$4,500,000
$10.0 P/Share
|
|
Feb 29
2024
|
Paul A. Grayson Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+22.41%
|
-
|
|
Feb 29
2024
|
Tuan Tu Diep Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+19.71%
|
-
|
|
Feb 29
2024
|
Kaitlyn Melanie Arsenault Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+10.61%
|
-
|
|
Feb 29
2024
|
Punit Dhillon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+20.12%
|
-
|
|
Jan 31
2024
|
Andrew J. Schwab Director |
BUY
Grant, award, or other acquisition
|
Indirect |
5,206,074
+39.59%
|
$10,412,148
$2.31 P/Share
|
|
Jan 31
2024
|
5 Am Partners Vii, LLC |
BUY
Open market or private purchase
|
Indirect |
5,206,074
+39.59%
|
$10,412,148
$2.31 P/Share
|
|
Nov 06
2023
|
Punit Dhillon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
194,270
+39.54%
|
-
|
|
Nov 06
2023
|
Kaitlyn Melanie Arsenault Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
128,209
+40.84%
|
-
|
|
Nov 06
2023
|
Paul A. Grayson Director |
BUY
Grant, award, or other acquisition
|
Direct |
173,721
+41.36%
|
-
|
|
Aug 29
2023
|
Punit Dhillon Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
881,000
+2.08%
|
$0
$0.02 P/Share
|
|
Aug 28
2023
|
Punit Dhillon Chief Executive Officer |
BUY
Small Acquisition
|
Direct |
110,000
+0.27%
|
$0
$0.02 P/Share
|
|
Aug 25
2023
|
Paul A. Grayson Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,132,596
+50.0%
|
-
|
|
Aug 25
2023
|
Kaitlyn Melanie Arsenault Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,382,118
+48.2%
|
-
|
|
Aug 25
2023
|
Punit Dhillon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,277,414
+33.33%
|
-
|
|
Aug 23
2023
|
Punit Dhillon Chief Executive Officer |
BUY
Small Acquisition
|
Direct |
9,000
+0.02%
|
$0
$0.01 P/Share
|
|
Aug 18
2023
|
Andrew J. Schwab Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,130,857,157
+40.95%
|
$0
$0.01 P/Share
|
|
Feb 22
2023
|
Emerald Health Sciences Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
58,020,650
+15.57%
|
$0
$0.03 P/Share
|
|
Nov 10
2022
|
Punit Dhillon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
2,335,721
+50.0%
|
-
|
|
Nov 10
2022
|
Punit Dhillon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,406,543
+24.2%
|
-
|
|
Nov 10
2022
|
Sukhwinder Singh Rai Director |
BUY
Grant, award, or other acquisition
|
Indirect |
95,718
+50.0%
|
-
|
|
Dec 14
2021
|
Kaitlyn Melanie Arsenault Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+50.0%
|
-
|
|
Dec 14
2021
|
Punit Dhillon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000,000
+40.0%
|
-
|